MUTÉINE DE LIPOCALINE POUR LE TRAITEMENT DE L'ASTHME

The present invention relates to the treatment of asthma in a human subject by administering by inhalation a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject, wherein the delivered dose of said lipocalin mute...

Full description

Saved in:
Bibliographic Details
Main Authors GARDINER, Philip, JAUHIANINEN, Aulikki Ingergard Alexandra, PARDALI, Ekaterina, BRUNS, Ingmar, MATSCHINER, Gabriele, AXELSSON, Lena Therese, FITZGERALD, Mary, OLSSON, Gunnel Marita, CLOSE, David Robert
Format Patent
LanguageFrench
Published 09.02.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the treatment of asthma in a human subject by administering by inhalation a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject, wherein the delivered dose of said lipocalin mutein, or variant or fragment thereof, is from about 0.1 mg to about 160 mg. The lipocalin mutein, or a variant or fragment thereof, may for example be administered at least once per day, once per day or twice per day.
Bibliography:Application Number: MA20200055490